A novel tumor-specific gene therapy for bladder cancer

Chong-Xian Pan, K. S. Koeneman

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Gene therapy has been successfully used to treat genetic diseases. Currently, much investigation involves the role of gene therapy in malignant tumors. One problem associated with the retroviral system used for gene therapy is its non-specificity. Herein a vector delivery system is described, using human telomerase reverse transcriptase (hTRT) promotor, which can specifically affect telomerase-positive tumor cells while sparing nearby telomerase-negative cells. By combining a self-containing Cre/loxP site-specific recombination system into the design, this vector will destroy telomerase-positive, p53-negative tumor cells, while sparing normal cells which are telomerase-positive with wild type p53 (such as activated lymphocytes). This vector design appears especially suited to bladder transitional cell carcinoma, because of easy access transurethrally and high rate of local recurrence, and biologically secondary to high proportion of telomerase activity and p53 dysfunction.

Original languageEnglish (US)
Pages (from-to)130-135
Number of pages6
JournalMedical Hypotheses
Issue number2
StatePublished - Aug 1999
Externally publishedYes

ASJC Scopus subject areas

  • Developmental Biology
  • Medicine(all)
  • Drug Discovery


Dive into the research topics of 'A novel tumor-specific gene therapy for bladder cancer'. Together they form a unique fingerprint.

Cite this